Emerald Advisers LLC Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Emerald Advisers LLC cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 518,328 shares of the biopharmaceutical company's stock after selling 51,470 shares during the quarter. Emerald Advisers LLC owned 0.56% of Ultragenyx Pharmaceutical worth $21,806,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Van ECK Associates Corp increased its holdings in Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 273 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock valued at $928,000 after purchasing an additional 294 shares during the period. Motley Fool Asset Management LLC raised its stake in Ultragenyx Pharmaceutical by 0.3% in the 3rd quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company's stock valued at $8,005,000 after purchasing an additional 360 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 493 shares during the last quarter. Finally, M&T Bank Corp raised its position in shares of Ultragenyx Pharmaceutical by 8.1% in the third quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company's stock valued at $388,000 after buying an additional 525 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Ultragenyx Pharmaceutical Stock Performance

RARE stock traded up $0.91 during mid-day trading on Thursday, reaching $38.89. The company had a trading volume of 558,142 shares, compared to its average volume of 779,236. The firm has a fifty day simple moving average of $41.68 and a 200 day simple moving average of $47.03. The company has a market capitalization of $3.60 billion, a price-to-earnings ratio of -6.13 and a beta of 0.67. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $36.71 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 1,785 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. This represents a 1.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now directly owns 54,991 shares in the company, valued at $2,358,014.08. This trade represents a 5.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 136,370 shares of company stock valued at $5,751,499 over the last quarter. 5.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wedbush restated a "neutral" rating and set a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. JPMorgan Chase & Co. lifted their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday. Piper Sandler decreased their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company increased their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research note on Friday, December 20th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.